A novel machine learning non-linear prognostic framework encoding somatic copy-number alterations and biological information associated with gene products, along with an integrative multi-omics approach including epigenomics and transcriptomics into a patient-specific biological network offers a prognostic tool to identify biologically aggressive prostate cancer disease within patients currently undertreated by standard risk criteria.
Abstract
Risk stratification in primary prostate cancer remains heavily reliant on clinicopathological criteria that frequently miss the heterogeneity underlying early aggressive disease. We present a novel machine learning non-linear prognostic framework encoding somatic copy-number alterations and biological information associated with gene products, along with an integrative multi-omics approach including epigenomics and transcriptomics into a patient-specific biological network. Applied to the TCGA-PRAD (n = 498), our weighted graph-based feature selection and LASSO-Cox model identified ZNF268 as a master regulator gene, in which the hypermethylation of its promoter region is linked to a distinct oncogenic transition exclusive to Low/Intermediate-risk disease. Post-hoc analysis of Low-ZNF268 tumors showed a distinct somatic landscape enriched for driver mutations and predicted sensitivity to MAPK, ATR, and PI3K/mTOR inhibitors, providing potential therapeutic vulnerabilities alongside the prognostic signal. Topological network analysis further revealed that ZNF268 loss impacts a co-expression rewiring gene network, quantified as a Rewiring Score: associated with Progression-Free Survival in the TCGA-PRAD (HR: 2.79, 95% CI: 1.36–5.71, p = 0.0049) and Biochemical Recurrence in two external cohorts. By capturing tumors at an active molecular transition state preceding systemic progression, this framework offers a prognostic tool to identify biologically aggressive prostate cancer disease within patients currently undertreated by standard risk criteria.
A three-gene signature provides a new exploratory prognostic model while inferring a COMP+ to NELL2+ transcriptional transition and demonstrates the value of AI-driven multi-omics integration for precision oncology.
Xue-Qian Zhang, Wei Zhang, Zheng Wang et al.· Genes· 0 citations
These findings establish eRNAs as a complementary noncoding layer to conventional messenger RNA classifiers, with clinical potential for breast cancer risk stratification, therapeutic guidance, and early detection.
Jun-Huan Xia, Jing-Wen Tian, Yu-Ting Cao et al.· NAR Cancer· 0 citations
Osteosarcoma is a highly malignant bone tumor characterized by significant clinical heterogeneity and poor prognostic outcomes. In this study, we integrated single-cell RNA sequencing data to characterize the landscape of genes related to N4-acetylcytidine (ac4C) modification. We calculated an acRG activity score and f...
Hong-Lei Xiao, Xiao-Long Yang, Mao-Bin Zhou et al.· Biochimica et Biophysica Act...· 0 citations
MZT1 is a proliferation-associated marker that integrates clinical risk, transcriptional programs, cellular heterogeneity, and predictive modeling in LUAD, providing a potential framework for biomarker development and risk stratification.
Dahlak Daniel Solomon, Hui-Ru Lin, Yung-Kuo Lee et al.· Cancer Genomics & Proteomics· 0 citations
Collectively, multi-modal plasma cfRNA profiling may enable non-invasive breast cancer detection and provide candidate markers for prognostic risk stratification and future precision oncology applications.
Jun Wang, Liu Yang, Kai Fang et al.· Genomics· 0 citations
This study integrates multi-omics and machine learning to highlight CPED1 as a promising candidate biomarker, with potential diagnostic and prognostic relevance in LUAD, and stratified patients by survival outcomes in the TCGA cohort.
Rakesh Arya, V. Biswas, Hemlata Shakya et al.· Genes· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.